Pulmonary Fibrotic Diseases This review covers fibrotic pulmonary diseases. Although
idiopathic pulmonary fibrosis is very common, the review focuses mainly on fibrotic diseases …

Although these conditions are rare, a proportion of patients with interstitial lung diseases
(ILDs) may develop a progressive-fibrosing phenotype. Progressive fibrosis is associated …

Background: This American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …

Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …

Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

Idiopathic pulmonary fibrosis (IPF) is a progressive and terminal lung disease with no known
cure. IPF is a disease of aging, with median age of diagnosis over 65 years. Median survival …

Background Based on international diagnostic guidelines, high-resolution CT plays a central
part in the diagnosis of fibrotic lung disease. In the correct clinical context, when high …

Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of develo**
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function …

This expert group consensus statement emphasises the need for standardising the definition
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …